JP2009531051A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009531051A5 JP2009531051A5 JP2009502200A JP2009502200A JP2009531051A5 JP 2009531051 A5 JP2009531051 A5 JP 2009531051A5 JP 2009502200 A JP2009502200 A JP 2009502200A JP 2009502200 A JP2009502200 A JP 2009502200A JP 2009531051 A5 JP2009531051 A5 JP 2009531051A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- library
- drug
- level
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- -1 SCBGB2A2 Proteins 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 3
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 3
- 102100021761 Alpha-mannosidase 2 Human genes 0.000 claims 2
- 102100039239 Amidophosphoribosyltransferase Human genes 0.000 claims 2
- 102100022549 Beta-hexosaminidase subunit beta Human genes 0.000 claims 2
- 102100040606 Dermatan-sulfate epimerase Human genes 0.000 claims 2
- 102100036241 HLA class II histocompatibility antigen, DQ beta 1 chain Human genes 0.000 claims 2
- 108010065026 HLA-DQB1 antigen Proteins 0.000 claims 2
- 101000615953 Homo sapiens Alpha-mannosidase 2 Proteins 0.000 claims 2
- 101001045433 Homo sapiens Beta-hexosaminidase subunit beta Proteins 0.000 claims 2
- 101000816698 Homo sapiens Dermatan-sulfate epimerase Proteins 0.000 claims 2
- 101001051207 Homo sapiens L-lactate dehydrogenase B chain Proteins 0.000 claims 2
- 101001042362 Homo sapiens Leukemia inhibitory factor receptor Proteins 0.000 claims 2
- 101001135344 Homo sapiens Polypyrimidine tract-binding protein 1 Proteins 0.000 claims 2
- 101001123146 Homo sapiens Serine/threonine-protein phosphatase 4 regulatory subunit 1 Proteins 0.000 claims 2
- 102100024580 L-lactate dehydrogenase B chain Human genes 0.000 claims 2
- 102100032352 Leukemia inhibitory factor Human genes 0.000 claims 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims 2
- 102100021747 Leukemia inhibitory factor receptor Human genes 0.000 claims 2
- 101150053046 MYD88 gene Proteins 0.000 claims 2
- 102100024134 Myeloid differentiation primary response protein MyD88 Human genes 0.000 claims 2
- 102000002356 Nectin Human genes 0.000 claims 2
- 108060005251 Nectin Proteins 0.000 claims 2
- 102100033073 Polypyrimidine tract-binding protein 1 Human genes 0.000 claims 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 2
- 102100028618 Serine/threonine-protein phosphatase 4 regulatory subunit 1 Human genes 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 239000000090 biomarker Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 108010049285 dephospho-CoA kinase Proteins 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000009368 gene silencing by RNA Effects 0.000 claims 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 230000035945 sensitivity Effects 0.000 claims 2
- 108091005646 acetylated proteins Proteins 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 208000022602 disease susceptibility Diseases 0.000 claims 1
- 239000000890 drug combination Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0606096.6A GB0606096D0 (en) | 2006-03-27 | 2006-03-27 | Screening method |
| GB0606096.6 | 2006-03-27 | ||
| PCT/GB2007/001086 WO2007110623A2 (en) | 2006-03-27 | 2007-03-27 | Screening method |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013087048A Division JP6017367B2 (ja) | 2006-03-27 | 2013-04-18 | スクリーニング法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009531051A JP2009531051A (ja) | 2009-09-03 |
| JP2009531051A5 true JP2009531051A5 (https=) | 2011-04-21 |
| JP5528103B2 JP5528103B2 (ja) | 2014-06-25 |
Family
ID=36384256
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009502200A Expired - Fee Related JP5528103B2 (ja) | 2006-03-27 | 2007-03-27 | スクリーニング法 |
| JP2013087048A Expired - Fee Related JP6017367B2 (ja) | 2006-03-27 | 2013-04-18 | スクリーニング法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013087048A Expired - Fee Related JP6017367B2 (ja) | 2006-03-27 | 2013-04-18 | スクリーニング法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US8784806B2 (https=) |
| EP (3) | EP2005162B1 (https=) |
| JP (2) | JP5528103B2 (https=) |
| AT (1) | ATE537445T1 (https=) |
| DK (2) | DK2005162T3 (https=) |
| ES (3) | ES2569663T3 (https=) |
| GB (1) | GB0606096D0 (https=) |
| WO (1) | WO2007110623A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1751115A4 (en) | 2004-05-23 | 2010-10-20 | Gerard M Housey | THERAMUTEINMODULATOREN |
| NZ589276A (en) | 2005-02-03 | 2012-06-29 | Topotarget Uk Ltd | Combination therapies using hdac inhibitors and erlotinib (tarceva) |
| CN101189003B (zh) | 2005-05-13 | 2012-02-08 | 托波塔吉特英国有限公司 | Hdac抑制剂的药物制剂 |
| JP5377968B2 (ja) | 2005-11-10 | 2013-12-25 | トポターゲット ユーケー リミテッド | 癌治療のために単独で用いるまたは化学療法薬と併用するヒストンデアセチラーゼ（ｈｄａｃ）阻害剤 |
| GB0606096D0 (en) | 2006-03-27 | 2006-05-03 | Cbmm Sa | Screening method |
| JP2010540426A (ja) | 2007-09-25 | 2010-12-24 | トポターゲット ユーケー リミテッド | 特定のヒドロキサム酸化合物の合成方法 |
| BR112015022737A2 (pt) * | 2013-03-11 | 2018-04-24 | Pioneer Hi-Bred International, Inc | construto de polinucleotídeo recombinante, célula vegetal, planta, semente, método para regular expressão |
| GB201306339D0 (en) * | 2013-04-08 | 2013-05-22 | Isis Innovation | Biomarkers for prognosis |
| GB2524519B (en) * | 2014-03-25 | 2019-11-06 | Pelago Bioscience AB | Methods for identifying a biomarker indicative of a reduced drug response using a thermal shift assay |
| ES2702432B2 (es) | 2017-08-31 | 2019-08-05 | Venegas Pedro Manuel Medina | Método y dispositivo para el análisis de ácidos nucleicos |
| GB201914517D0 (en) * | 2019-10-08 | 2019-11-20 | Randox Laboratories Ltd | Xbp1 isoform multiplex assay |
| CA3258625A1 (en) * | 2022-07-27 | 2024-02-01 | E-Therapeutics Plc | ZPI INHIBITANT DOUBLE-STRANDED NUCLEIC ACID COMPOUNDS |
| CN116949169B (zh) * | 2023-07-31 | 2024-02-06 | 山东大学齐鲁医院 | Smek1在缺血性脑卒中诊治中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050123896A1 (en) | 2001-10-25 | 2005-06-09 | Benz Christopher C. | Screening system for modulators of her2 mediated transcription and her2 modulators identified thereby |
| US20030186903A1 (en) | 2001-11-23 | 2003-10-02 | Isis Pharmaceuticals Inc. | Antisense modulation of MyD88 expression |
| AU2003214055A1 (en) * | 2002-02-08 | 2003-09-02 | Novartis Ag | Method for screening for compounds having hdac inhibitory activity |
| US20040132825A1 (en) * | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
| US7229617B2 (en) | 2002-11-27 | 2007-06-12 | Irm Llc | Methods and compositions for inducing apoptosis in cancer cells |
| US20080233562A1 (en) | 2003-02-19 | 2008-09-25 | Astellas Pharma Inc. | Method of Estimating Antitumor Effect of Histone Deacetylase Inhibitor |
| CA2535889A1 (en) * | 2003-08-29 | 2005-03-17 | Aton Pharma, Inc. | Combination methods of treating cancer |
| GB0401876D0 (en) | 2004-01-28 | 2004-03-03 | Vereniging Het Nl Kanker I | New use for cancer antigen |
| EP2520652B1 (en) * | 2004-04-09 | 2015-06-10 | Genecare Research Institute Co., Ltd | Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associates genes |
| WO2005100609A2 (en) * | 2004-04-15 | 2005-10-27 | Rosetta Inpharmatics Llc | Methods for identifying genes that mediate a response of a living cell to an agent |
| CA2574044A1 (en) | 2004-07-19 | 2006-02-23 | Schering Corporation | Myd88 as a therapeutic target for cancer |
| SG156625A1 (en) * | 2004-12-08 | 2009-11-26 | Aventis Pharma Inc | Method for measuring resistance or sensitivity to docetaxel |
| US7985538B2 (en) | 2006-02-23 | 2011-07-26 | Yale University | Drug resistance and methods of reversing |
| GB0606096D0 (en) | 2006-03-27 | 2006-05-03 | Cbmm Sa | Screening method |
-
2006
- 2006-03-27 GB GBGB0606096.6A patent/GB0606096D0/en not_active Ceased
-
2007
- 2007-03-27 DK DK07732147.9T patent/DK2005162T3/da active
- 2007-03-27 WO PCT/GB2007/001086 patent/WO2007110623A2/en not_active Ceased
- 2007-03-27 AT AT07732147T patent/ATE537445T1/de active
- 2007-03-27 ES ES11162743.6T patent/ES2569663T3/es active Active
- 2007-03-27 ES ES07732147T patent/ES2376912T3/es active Active
- 2007-03-27 ES ES13194854.9T patent/ES2607753T3/es active Active
- 2007-03-27 EP EP07732147A patent/EP2005162B1/en not_active Not-in-force
- 2007-03-27 JP JP2009502200A patent/JP5528103B2/ja not_active Expired - Fee Related
- 2007-03-27 US US12/294,603 patent/US8784806B2/en active Active
- 2007-03-27 EP EP13194854.9A patent/EP2733491B1/en not_active Not-in-force
- 2007-03-27 EP EP11162743.6A patent/EP2365335B1/en not_active Not-in-force
- 2007-03-27 DK DK13194854.9T patent/DK2733491T3/en active
-
2013
- 2013-04-18 JP JP2013087048A patent/JP6017367B2/ja not_active Expired - Fee Related
-
2014
- 2014-06-16 US US14/306,137 patent/US9347103B2/en not_active Expired - Fee Related
-
2016
- 2016-04-29 US US15/143,435 patent/US10012652B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009531051A5 (https=) | ||
| Krueger et al. | A randomized, placebo-controlled study of SRT2104, a SIRT1 activator, in patients with moderate to severe psoriasis | |
| Sullivan et al. | Trisomy 21 consistently activates the interferon response | |
| US20200232045A1 (en) | Methods of identifying individuals at increased risk of lung cancer | |
| Adua et al. | Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer | |
| Wang et al. | Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein | |
| Sun et al. | Oncogenic function of TRIM2 in pancreatic cancer by activating ROS-related NRF2/ITGB7/FAK axis | |
| JP2012500389A5 (https=) | ||
| WO2017165199A1 (en) | Next-generation biomarkers to detect sun damage and predict skin cancer risk | |
| JP2011517932A5 (https=) | ||
| JP2008537474A5 (https=) | ||
| Bukhari et al. | PINTology: A short history of the lncRNA LINC‐PINT in different diseases | |
| Batchu et al. | Lung and kidney ACE2 and TMPRSS2 in renin-angiotensin system blocker–treated comorbid diabetic mice mimicking host factors that have been linked to severe COVID-19 | |
| Xu et al. | The deubiquitinating enzyme USP1 is auto-ubiquitinated and destabilized by ML323 in colorectal cancer cells | |
| JP2006505241A (ja) | Ｈｄａｃ阻害活性を有する化合物のスクリーニング法 | |
| Voic et al. | RNA sequencing identifies common pathways between cigarette smoke exposure and replicative senescence in human airway epithelia | |
| JP2012507268A5 (https=) | ||
| JP2015505669A5 (https=) | ||
| Zapater et al. | Micro-RNA in obstructive sleep apnoea: biomarker of cardiovascular outcome? | |
| US20160222466A1 (en) | Activities of multiple cancer-related pathways are associated with braf mutation and predict the resistance to braf/mek inhibitors in melanoma cells | |
| WO2011137302A1 (en) | Methods for identifying aberrantly regulated intracellular signaling pathways in cancer cells | |
| Huang et al. | ZUP1 promotes DNA repair and immune evasion to drive olaparib resistance in triple-negative breast cancer | |
| Abe et al. | Genetic variation in the activity of a TREM2–p53 signaling axis determines oxygen-induced lung injury | |
| JP2005525790A5 (https=) | ||
| US20250295651A1 (en) | Methods of using alternating electric fields in combination with temozolomide and a checkpoint inhibitor |